|
2004
OMIG, Abstract 1
OMIG
Main Page | 2004
Abstracts | < Previous | Next
>
A Novel Topical
Antiviral Agent, PCL-016 (Picolinic Acid), Inhibits Adenovirus Replication
in the Ad5/NZW Rabbit Ocular Model
EG Romanowski, KA Yates, RP Kowalski, FS Mah, YJ Gordon. The Charles
T. Campbell Laboratory, University of Pittsburgh, Pittsburgh, PA
Purpose:
The need for an effective antiviral to treat adenovirus (Ad) ocular
infections persists. The goal of the current study was to determine
the antiviral efficacy of a novel topical antiviral agent, PCL-016
(PCL, Picolinic Acid) a pyridine carboxylate that binds with the
zinc associated with Zinc Finger Proteins to affect their structure
and function, on acute adenovirus(Ad) replication in the Ad5/NZW
rabbit ocular model.
Methods: 25 NZW rabbits were topically inoculated
in both eyes, following corneal scarification, with 1.5 x 106 pfu/eye
of Ad5. On day 1, the rabbits were divided into 6 topical treatment
groups: I - 1.5% PCL pH 7.0 (n=4); II - 0.8% PCL pH 7.0 (n=4); III
- 0.369% PCL pH 7.0 (n=4); IV - 0.369% PCL pH 4.0 (n=4); V - 0.5%
Cidofovir (CDV) (n=4); VI - Control (saline) (n=5). PCL and Control
rabbits
were treated QID x 7 days, while CDV rabbits were treated BID x
7 days. All eyes were cultured for virus on days 0, 1,3, 4, 5, 7,
9, 11, and 14.
Results: |
|
|
Group |
Ad
+ Cultures/Total
(Days 1-14) |
Duration
of Ad
Shedding (Days) |
1.5%
PCL |
30/64
(47%)* |
5.9 ±
3.6* |
0.8%
PCL |
31/64
(48%)* |
7.0 ±
3.5* |
0.369%
PCL (pH7) |
32/64
(50%)* |
8.6 ±
4.4* |
0.369%
PCL (pH4) |
33/64(52%)* |
9.1 ±
2.5** |
0.5%
CDV |
25/64(39%)* |
5.8 ±
2.9* |
Control |
64/80(84%) |
12.3
± 1.9 |
*p
< 0.001 compared to the Control. **p = 0.001 compared to
CDV. |
Conclusions:
Topical 1.5% PCL, 0.8% PCL, 0.369% PCL (pH7), 0.369% PCL (pH4) and
0.5% CDV were significantly more effective than the Control in reducing
Ad Positive Cultures/Total (Days 1-14) and the Duration of Ad Shedding
in the Ad5/NZW rabbit ocular model. Although not statistically significant,
there appears to be concentration-dependent efficacy of PCL on the
Duration of Ad Shedding. There was no apparent ocular toxicity associated
with PCL concentrations. Additional studies of PCL in the experimental
Ad5/NZW ocular model are indicated.
Disclosure code: F, C Support: Novactyl, Inc., NIH EY05323, EY08098
OMIG
Main Page | 2004
Abstracts | < Previous | Next
>
|
|
|